 | Up a level |
Journal Article
Theurich, S., Mueller, P., Martin, K., Savic, S., Terszowski, G., Lardinois, D., Schlaak, M., Stadler, R., Kvasnicka, H. -M., Spagnoli, G., Dirnhofer, S., Speiser, D. E., von Bergwelt-Baildon, M. and Zippelius, A. (2014). Beyond cytotoxicity: Implications for immune mediated mechanisms of action of brentuximab vedotin treatment in CD30(+) lymphomas. Oncol. Res. Treat., 37. S. 31 - 32. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Rothschild, S. I., Hoffmann, M., Fabri, M., Sommer, A., Marquez, M. Garcia, Thelen, M., Schill, C., Merki, R., Schmid, T., Koeberle, D., Zippelius, A., Baues, C., Mauch, C., Tigges, C., Kreuter, A., von Bergwelt-Baildon, M. and Schlaak, M. (2016). Cytotoxic local tumor treatment in combination with xystemic Ipilimumab enhances the efficacy of this immunotherapy and prolongs overall survival in patients with advanced malignant melanoma. Oncol. Res. Treat., 39. S. 8 - 9. BASEL: KARGER. ISSN 2296-5262
Theurich, S., Rothschild, S., I, Hoffmann, M., Fabri, M., Sommer, A., Garcia-Marquez, M., Thelen, M., Schill, C., Merki, R., Schmid, T., Koeberle, D., Zippelius, A., Baues, C., Mauch, C., Tigges, C., Kreuter, A., Borggrefe, J., Schlaak, M. and von Bergwelt-Baildon, M. (2016). Local treatment of tumors or metastases in combination with systemic ipilimumab immunotherapy prolongs overall survival in patients with advanced malignant melanoma. Oncol. Res. Treat., 39. S. 103 - 105. BASEL: KARGER. ISSN 2296-5262